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Muscle relaxation and neuromuscular block 
Surgical anaesthesia usually requires hypnosis, antinociception (ensuring blood pressure and heart 
rate control) and immobility with varying degrees of muscle relaxation. However, the relative 
contribution of these three components to the state of anaesthesia may vary between different 
anaesthesias and surgical procedures. While volatile anaesthetics may be used to produce 
anaesthesia in and by themselves, most often anaesthesia is produced by a combination of drugs. 
Anaesthesia produced by the concomitant use of hypnotics, analgesics and neuromuscular 
blocking drugs is called “balanced anaesthesia”. 
 
The degree of neuromuscular block induced by neuromuscular blocking drugs and the depth of 
anaesthesia (induced by other drugs) both affect muscle relaxation[1]. While in the early days of 
our profession deep ether anaesthesia alone provided sufficient muscle relaxation for many 
procedures, the introduction of neuromuscular blocking drugs nowadays allows us to specifically 
target specific degrees of muscle relaxation in an easy and safe manner. Provided the airway is 
secured and adequate ventilation and hypnosis are ensured, adverse effects of neuromuscular 
blocking drugs are few. 
 
After briefly reviewing pertinent physiology, the different degrees of neuromuscular block depth 
are defined and the tools to measure them are described. The chapter then focuses on the 
properties of modern neuromuscular blocking drugs (only cisatracurium, mivacurium, and 
rocuronium will be discussed) and suxamethonium. Finally, the clinically optimal neuromuscular 
block is defined, and the different routes to achieve this goal are explored. 
Neuromuscular junction 
An action potential causes synaptic vesicles of the motor nerve endings containing the 
neurotransmitter acetylcholine to fuse with the plasma membrane and release their content into 
the neuromuscular junction. Acetylcholine then binds to postjunctional nicotinic acetylcholine 
receptors on the motor endplate. These receptors consist of two alpha and one beta, delta and 
epsilon subunits. They are directly linked to ion channels. If acetylcholine is bound to both alpha 
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subunits, the permeability of the ion channel for Na+ and K+ ions increases, depolarizing the 
muscle cell[2]. Subsequent calcium release causes contraction of the cell, and if a sufficient number 
of muscle cells are depolarized simultaneously, muscle contraction ensues. 
 
In addition to the postjunctional receptors, there are also prejunctional acetylcholine receptors 
that are involved in the modulation of acetylcholine release in the neuromuscular junction. They 
consist of three alpha and two beta subunits. While clinically used non-depolarizing 
neuromuscular blocking drugs have affinity for these presynaptic receptors, the only available 
depolarizing neuromuscular blocking drug, suxamethonium, has not[3]. Because a non-depolarizing 
neuromuscular block displays fade after train of four stimulation (see further) while a 
suxamethonium induced neuromuscular block does not, it is plausible to explain this by the 
aforementioned different effects on presynaptic nicotinic acetylcholine receptors. Fade is used to 
quantify the degree of neuromuscular block elicited by the non-depolarizing neuromuscular 
blocking drugs. 
 
Quantification of neuromuscular block 
Because the individual response to neuromuscular blocking drugs varies to such an extent that it 
becomes unpredictable in the individual patient, neuromuscular function has to be measured 
continually during anaesthesia. Fortunately, of all components making up anaesthesia, the degree 
of the neuromuscular block is the one that can be quantified most easily by applying a 
supramaximal electrical stimulus to a peripheral motor nerve and quantifying the subsequent 
muscle contraction (or other muscle response). A complete or partial neuromuscular block is said 
to exist if no or some (but not a full) response is present, respectively.  
 
After administration of a neuromuscular blocking drug, the degree of neuromuscular block is not 
uniform in all muscles throughout the body. For example, laryngeal muscles achieve peak effect 
faster than peripheral muscles but the effect there also dissipates faster. Both pharmacokinetic 
(e.g. blood flow) and pharmacodynamic (sensitivity) factors account for these differences. These 
differences have to be taken into account when monitoring neuromuscular block in one muscle 
(because ease of access, e.g.) to get an idea of the neuromuscular block in another muscle that 
may be the more relevant one to ensure optimal surgical conditions – it explains why the 
quantification of neuromuscular block at hand is not perfectly informative for neuromuscular 
block at diaphragm or abdominal wall[4]. 
Stimulation patterns 
While quantifying the muscle response following electrical stimulation of a motor nerve seems 
rather straightforward, in reality it is a rather complex subject. 
 
While a number of stimulation patterns are in widespread use, the type of electrical stimulation is 
often quite similar. Typically, a unipolar constant-current pulse is used, and this current has to be 
strong enough to evoke a supramaximal response from the muscle. The reason for the need of 
supramaximal stimulation is to ensure that the magnitude of muscle contraction is independent of 
the intensity of the electrical stimulation. If all of the motor units innervated by the stimulated 
nerve are recruited, then we have supramaximal stimulation. The magnitude of the contraction 
then (ideally) becomes independent of the magnitude of the electrical stimulus. Under these 
conditions, the only limiting factor in muscle contraction is the neuromuscular transmission, which 
is the characteristic of interest. This method also reduces the dependence of muscle contraction 
on stimulating electrode conditions which can vary during the surgical procedure. Moisture or gel 
under the electrodes changes the electrical properties of the skin under the electrodes. Typically, 
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constant-current pulses of up to 50-60 milliamperes are used with duration of 200-300 
microseconds. 
 
Ideally, both the stimulation site (= site where electrodes are placed) and the monitoring site (= 
site where muscle response is registered) have to remain easily accessible throughout the surgical 
procedure. Because during most surgical procedures at least one hand is accessible, the ulnar 
nerve at the wrist and the adductor pollicis it innervates are the most commonly used monitoring 
sites. When this site is not accessible, the orbicularis oculi or corrugator supercilii at the eye, and 
the flexor hallucis brevis at the foot can be used. Accessibility of the area of the motor nerve is 
important for the initial electrode placement, but once the electrodes are placed, often the site 
does not need repeated access. 
Single-twitch stimulation 
Single-twitch stimulation refers to the application of a single electrical pulse to a motor nerve, 
with quantification of the resulting muscle contraction called “single-twitch-response”. Before the 
administration of neuromuscular blocking drugs, a “control twitch” is determined that serves as 
the baseline muscle contraction to which subsequent twitches are referenced. A value of 0% 
indicates complete neuromuscular block, and 100% indicates no neuromuscular block. While 
single-twitch stimulation has been used extensively in older research, it has only been rarely 
applied in routine clinical practice. A proper understanding of this method helps the clinician to 
gain insight into much of the research on neuromuscular blocking drugs. 
 
The interpretation of the single-twitch stimulation response is confounded by “twitch 
potentiation”, a physiological phenomenon whereby repetitive stimulation can cause a gradual 
increase in twitch response that ultimately plateaus. To make matters even more complex, the 
magnitude of the control twitch response may also depend on the stimulation pattern. Because 
intra-operative neuromuscular transmission monitoring requires repetitive stimulation of the 
nerve, post-relaxation twitch responses (= responses during and after the recovery of 
neuromuscular block) will be potentiated and plateau at some higher value. If insufficient time is 
taken for twitch response stabilization prior to the administration of neuromuscular blocking 
drugs, twitch potentiation during and after recovery of a drug-induced neuromuscular block can 
result in a twitch response that exceeds the control twitch (obtained prior to the administration of 
neuromuscular blocking drugs) by 150-180%. In these conditions, a twitch response of 100% of the 
control twitch will falsely indicate full recovery and underestimate a residual block that may still 
cause the patient to experience clinical signs of residual neuromuscular block.  
 
“Pre-relaxation twitch stabilization” will eliminate “twitch potentiation” as a confounding factor 
when interpreting twitch responses after the administration of neuromuscular blocking drugs, but 
reaching a plateau can require up to 30 min of 0.1-Hz single-twitch simulation. Increasing the 
stimulation frequency can speed up the rate at which a plateau is reached but may also affect the 
ultimate plateau height as well. Careful balancing of these effects can be helpful in achieving a 
stable “control” twitch response before the administration of neuromuscular blocking drugs. A 2-
second 50-Hz tetanic stimulus followed by 2 minutes of 0.1-Hz stimulus has been suggested to 
reasonably rapid twitch stabilization[5,6]. Some researchers create a mathematical model of the 
postsynaptic process that causes a rise towards a plateau and incorporate it in their models of 
muscle relaxation[7]. 
Train-of-four stimulation pattern 
The difficulties of obtaining and interpreting the “control-twitch” for single-twitch stimulation 
have led to the development of the train-of-four (TOF) stimulation pattern. This stimulation 
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pattern consists of 4 electrical pulses separated by 0.5 seconds, with each train usually separated 
by 12-20 seconds. As the depth of a non-depolarizing neuromuscular block increases, the fourth 
twitch will diminish first because the previous 3 stimuli have depleted the acetylcholine content of 
the presynaptic vesicles, causing a preponderance of the competitive inhibitor at the 
neuromuscular junction. As the concentration of the competitive inhibitor (= non-depolarizing 
neuromuscular blocking drug) further increases and the block deepens, the third, second and first 
twitch responses also decrease (in that sequence, because less and less acetylcholine is available 
during each subsequent pulse in the train-of-four sequence). The origin of the TOF “fade” is 
thought to be a prejunctional effect of non-depolarizing neuromuscular blocking drugs. 
 
The TOF stimulation pattern eliminates the need for a pre-relaxation control twitch because it 
references the magnitude of the fourth to the first twitch and uses this ratio to quantify the depth 
of a neuromuscular block. This ratio is known as the TOF ratio. A TOF ratio of 100% indicates the 
absence of neuromuscular block and 0% indicates that the fourth twitch has disappeared, 
suggesting a moderately deep level of neuromuscular block. At deeper levels, the third, second 
and first twitches become progressively smaller and ultimately disappear. As recovery from 
neuromuscular block occurs, the twitches reappear in order and when the fourth twitch reappears 
the TOF ratio can be again calculated. Even with a TOF ratio of 1, a significant number of 
acetylcholine receptors may be blocked. It reflects the considerable margin of safety of 
neuromuscular transmission: up to 80% of receptors may be blocked without a noticeable effect 
on muscle strength. It also explains why the top-up dose of a neuromuscular blocking drug to 
maintain a certain block is only a fraction of the initial dose (see further). 
 
When the fourth twitch disappears and the so-called TOF count becomes 3 (out of 4) and the TOF 
ratio becomes 0%; a “moderately deep” block is said to exist. Once the TOF ratio becomes 0, the 
ratio itself cannot be used to quantify deeper blocks, and the clinician reverts to counting the 
number of detectable twitch responses after TOF stimulation, with a TOF count of 3, 2, 1, and 0 
indicating a progressively deeper block. A TOF-count of 0 or 1 corresponds to moderately deep 
neuromuscular block and indicates that considerable time must elapse before the fourth twitch 
will reappear and a TOF-ratio can be calculated. 
Tetanic stimulation pattern 
Even when TOF-count is 0, deeper levels of neuromuscular block can be monitored still with a 
post-tetanic count (PTC) stimulation pattern. To obtain a PTC, a supramaximal tetanic stimulation 
pattern of 50 Hz for 5 seconds is followed by a 3 second pause, after which a single-twitch 1 Hz 
stimulus is applied for 15 seconds. The number of muscle responses to the 1 Hz stimuli is related 
to the time of reappearance of the first twitch of a TOF stimulus[8]. 
 
Tetanic stimulation overcomes a deep non-depolarizing block by inducing by a process called 
“post-tetanic facilitation”: tetanic stimulus induced exhaustion of presynaptic vesicles accelerates 
recycling and synthesis of acetylcholine in the prejunctional synapse, a process that actual 
overshoots in the sense that a larger than normal amount of acetylcholine is released after a 
subsequent single twitch. This excessive amount of acetylcholine succeeds in overcoming a deep 
(competitive, non-depolarizing) neuromuscular block. Very deep levels of neuromuscular block 
can be quantified in this manner. A PTC of 1-2 suggests that considerable time still is needed 
before reappearance of the first twitch response to a TOF stimulus. The PTC pattern is typically 
preceded by a number of TOF stimulations and the tetanic stimulation of the PTC is only applied if 
no detectable responses are observed. 
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Quantification of the response to stimulation: the muscle response  
Following stimulation of a motor nerve, muscle response can be detected and quantified in a 
number of ways. Each method has various advantages and disadvantages. 
Manual or visual estimation 
The clinician can simply feel or observe the muscle contraction. However, manual estimation is not 
particularly accurate – even experienced researchers cannot observe fade at TOF ratios higher 
than about 40%[9]. Because current standards mandate that TOF ratios exceed 90%[10,11] at the end 
of a procedure, manual or visual estimation is insufficient to judge whether recovery is adequate. 
Manual estimation is acceptable to monitor deep levels of neuromuscular block with the PTC 
stimulation pattern. It is generally accepted though that state-of-the-art neuromuscular 
monitoring requires objective quantification of muscle contraction. 
Mechanomyography 
Mechanomyography (MMG) measures the peak isometric muscle force after supramaximal 
neuromuscular stimulation. MMG is considered the “gold-standard” of neuromuscular monitoring 
because it is the generation of muscle force that maintains the airway and effective contraction of 
diaphragm[12]. However, despite its importance, there are no commercially available devices that 
use isometric MMG neuromuscular monitoring. MMG has been used for research purposes 
though. 
 
Typically, the peak isometric muscle force of the thumb’s adductor pollicis is measured after 
stimulating the ulnar nerve at the elbow or at the wrist. MMG requires the associated limb to 
remain immobile. The thumb is held immobile by fixing the forearm to an arm-board, and force is 
measured using a strain gauge at the thumb[13]. The resting-tension of the muscle or “preload” 
influences the muscle force that is generated – it is generally accepted that a preload associated 
muscle length of 100-125% of resting length generates maximum muscle force. At the adductor 
pollicis, this corresponds to a preload of approximately 200 grams, and ideally this should vary less 
than 25% throughout the period of neuromuscular monitoring. Obviously, the force of the preload 
is not exclusively conveyed to the muscle - some force is transferred to connective tissues as well. 
The geometry of any joints of the system also plays a role in the force produced. A drawback of 
the arm-board system is that subtle changes in patient positioning can change the placement of 
the forearm within the arm-board, which changes the resting-tension, which in turn affects 
interpretation of the observed muscle force. 
 
Non-isometric mechanomyography 
Related to MMG monitoring is mechanical sensing of the muscle response. In this approach 
muscle contraction causes bending or compression of a piezoelectric sensor. It is used in the 
clinically widely applied NMT MechanoSensor (GE Healthcare, Finland) (Figure 11.1). The 
transducer is available in adult and paediatric sizes. Muscle preload cannot be evaluated because 
this depends of the mechanical properties of the transducer and how it matches with the 
individual anatomy. However, this approach does make attaching the device to the patient 
considerably simpler than for isometric systems, is much less sensitive to variation in patient 
positioning, and – even though it does not measure isometric muscle force - is sufficiently accurate 
for clinical applications. 
Acceleromyographic (AMG) measures 
If the limb associated with a muscle is free to move when the motor nerve is stimulated, then the 
movement of the limb can be also used to quantify muscle response. Acceleration is related to 
muscle force through Newton’s second law, force = mass acceleration. Because mass remains 
 6 
constant, the peak acceleration must be proportional to the peak muscle force resulting from the 
activation of the motor nerve. Accelerometers are robust, wear and tear free, and inexpensive to 
manufacture, making them well suited for the harsh clinical environment. They are also small, 
allowing considerable flexibility in how they can be placed: event though most commonly used to 
measure thumb adduction, they can also be applied to the obicularis occuli, corrugator supercilii 
and the flexor hallucis brevis muscles. Many patient monitors have integrated modules which 
quantify the degree of neuromuscular block with accelerometry. 
Electromyographic measures 
Prior to generating force, action potentials propagate throughout the muscle, initiating calcium 
release from the sarcoplasmic reticulum. These action potentials can also be detected and used to 
quantify the muscle’s response to neuromuscular stimulation. The summation of the action 
potentials can be recorded using electrodes placed over the belly of the activated muscle. The 
peak-to-peak amplitude or the integration of the surface underneath the electromyographic 
(EMG) signal can be used to quantify muscle response. The ulnar nerve is stimulated at the elbow 
or wrist and the EMG response captured with electrodes placed over the adductor pollicis (at the 
thenar eminence), the abductor digiti minimi (at the hypothenar eminence), or at the first dorsal 
interosseus muscle. An active recording electrode should be placed over the muscle and a ground 
electrode between the stimulation and the recording electrodes. Sources of artefacts are multiple. 
External pressure on or moving of the electrodes and the arm can make the EMG quantification 
unreliable, but can be avoided by properly shielding and immobilizing the arm and electrodes. 
Changes in temperature, electrode conditions (due to e.g. absorption of electrode gel and 
sweating) and monopolar diathermy can all interfere with EMG monitoring. 
 
Neuromuscular diseases can make EMG neuromuscular monitoring problematic. Volatile 
anaesthetics can impair muscle function and force generation without having an effect on the 
EMG signal[14,15]. In general, MMG and AMG rather than EMG are often preferred as techniques to 
monitor the degree of a neuromuscular block because they measure the actual movement in 
muscles. 
 
Pharmacology of neuromuscular blocking drugs 
Several drugs can prevent the contraction of skeletal muscles at the neuromuscular junction by 
inhibiting the synthesis or release of acetylcholine or by blocking its actions at the postjunctional 
membrane. Clinically used neuromuscular blocking drugs mainly act by the latter mechanism, 
inhibition of the postjunctional actions of acetylcholine at the nicotinic acetylcholine receptor. 
Two classes of neuromuscular blocking drugs exist, non-depolarizing and depolarizing. Only one 
depolarizing drug is clinically used, suxamethonium (also called succinylcholine). These two drug 
classes have different properties. 
 
All neuromuscular blocking drugs are quaternary ammonium compounds that hold acetylcholine 
somewhere in their chemical structure. The quaternary ammonium (NH4+) prevents their 
absorption from the gastrointestinal tract, placenta and into the cerebrospinal fluid. Because of 
these chemical properties, neuromuscular blocking drugs are not widely distributed in the body 
and their volume of distribution (0.1-0.5 l/kg) is rather close to the volume of extracellular fluid[17].  
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Non-depolarizing neuromuscular blocking drugs 
Mechanism of action 
Chemically, non-depolarizing neuromuscular blocking drugs are either benzylisoquinolones 
(cisatracurium, mivacurium) or aminosteroid derivatives (rocuronium). They are competitive 
inhibitors of acetylcholine at the postjunctional nicotinic receptor. If they occupy one or both 
alpha subunits, ion channel opening is prevented and neuromuscular transmission becomes 
impaired. At higher concentrations they can also block the channel directly, in a non-competitive 
action. However, this so-called “channel block” is of minor clinical significance[16].  
 
Adverse effects 
The action of non-depolarizing neuromuscular blocking drugs on nicotinic receptors outside the 
neuromuscular endplate or on muscarinic receptors explain many of their adverse effects. 
Cisatracurium, mivacurium and rocuronium have essentially no effects on nicotinic receptors in 
the autonomic ganglia (Table 1). Via an effect on the vagal nerve, rocuronium can activate cardiac 
muscarinic receptors, but tachycardia will only ensue at a dose which is 3-5-fold higher than a 
usual dose for endotracheal intubation. Benzylisoquinolones can cause serosal mast cells to 
release histamine, but this effect is mild with mivacurium and absent with cisatracurium. Overall, 
the incidence of serious adverse effects is low. Of all intraoperative life-threatening anaphylactic 
or anaphylactoid reactions (1 in 10000 to 20000 anaesthetics in a French study), 60% are caused 
by neuromuscular blocking drugs[17]. 
 
Pharmacokinetics and pharmacodynamics of non-depolarizing neuromuscular blocking drugs 
Essential basic pharmacokinetic and pharmacodynamic characteristics are summarized in Table 1. 
Renal clearance accounts for 10-25% of the elimination of rocuronium[18] , with the remainder 
being excreted into bile unchanged or after metabolization by the liver. While its metabolism 
remains poorly understood, increased rocuronium requirements in patients ingesting enzyme 
inducing drugs indicate that rocuronium is at least partly metabolized by the inducible microsomal 
enzymes in liver. Cisatracurium is degraded by Hoffman elimination, a chemical process 
independent of renal or hepatic function. Mivacurium is metabolized by plasma 
pseudocholinesterase, which explains why its plasma clearance (5 l/min in healthy adults) exceeds 
liver blood flow. 
 
Simultaneous pharmacokinetic-dynamic modelling has been used to give a full description of the 
pharmacological properties of neuromuscular blocking drugs. Population pharmacokinetics is a 
powerful tool to identify quantitatively which factors affect the pharmacokinetics and 
pharmacodynamics of various drugs. The major strength of the population approach is that useful 
information can be extracted even from sparse data using blood samples and pharmacologic 
monitoring during routine efficacy studies conducted during the development of a drug. Table 2 
shows the population pharmacokinetic and pharmacodynamic variables for non-depolarizing 
neuromuscular blocking drugs.  
 
The model parameters shown in Table 2 allow computer simulations to be performed of the 
behaviour of neuromuscular blocking drugs following any proposed administration regime. 
Compartmental volumes V1 (central), V2 and V3 (peripheral) represent drug distribution volumes, 
where the drug is administered (central) and where it can diffuse or be transported while in the 
body. These may have vague associations with different tissues in the body due to various factors 
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such as differing solubilites and other drug-tissue interactions. In any case they represent a rather 
extreme simplification of the complex biological processes underlying drug distribution.  
 
Model clearance parameters such as CL (elimination), Q2 and Q3 (inter-compartmental) represent 
drug transport between the various compartments, with CL being a special case of drug transport 
from the central compartment out of the body or otherwise made inactive. Drugs with a higher CL 
tend to have shorter duration or action in a straightforward manner. Interestingly, they also tend 
to have a more rapid onset of paralysis because these drugs allow greater initial doses, creating a 
stronger driving force for drug distribution to the effect compartment. The rate of drug 
distribution to the effect site, described as ke0, also plays an essential role in determining a drug’s 
potential for rapid onset of effect. A slow ke0 limits the rate of onset of action. While a simple 
first-order rate constant is often sufficient to describe drug transport to the effect site, 
mivacurium is an exception to this, requiring modelling of an interstitial compartment for accurate 
prediction of pharmacodynamics[19]. Other PD parameters describe various characteristics of drug 
effect. Ce50 describes the effect-site concentration at which 50% of drug effect is achieved. Lower 
values for Ce50 indicate higher drug potency. Parameter λ describes the slope of the sigmoidal 
Emax PD model. High values of λ indicate that drug effect changes rapidly over a low range of drug 
concentrations, creating an “on-off switch” like drug effect. Lower values of describe a more 
gradual relationship between effect-site concentration and drug effect.   
 
To highlight the pharmacokinetic-pharmacodynamic differences between two neuromuscular 
blocking drugs with an intermediate duration of action, we have simulated the course of effect 
site concentrations after the administration of one ED95 dose of either rocuronium or 
cisatracurium. We also simulated context-sensitive 50% effect decrement times as a function of 
the duration of infusion which maintained neuromuscular block (and effect site concentration) 
constant (Figure 11.2). 
 
Clinical pharmacology of non-depolarizing neuromuscular blocking drugs 
Mivacurium has a shorter duration of action than rocuronium and cisatracurium, whose duration 
of action is considered “intermediate" (Table 1). However, because rocuronium has the shortest 
onset of action of all three drugs, it is the more frequently used drug, especially if rapid 
endotracheal intubation is required.  
 
While cisatracurium has often been considered the drug of choice in patients having severe renal 
and/or hepatic dysfunction because of its organ-independent elimination, rocuronium can be used 
as well if the degree of neuromuscular block is monitored properly. 
 
Non-depolarizing neuromuscular blocking drugs are most often used to provide neuromuscular 
block during balanced anaesthesia. Provided hypnosis is provided by other means, they may also 
be used to provide immobility during diagnostic procedures or during transportation of critically ill 
patients, and occasionally to facilitate ventilation during intensive care. 
 
Depolarizing neuromuscular blocking drugs 
Mechanism of action 
The onset of action of suxamethonium is fast. Stimulation of the acetylcholine receptors usually 
results in visible fasciculations before the onset of muscle relaxation. Suxamethonium causes a 
long-lasting depolarization which prevents the muscular contraction. Experimentally, a similar 
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effect can be produced by the administration of acetylcholine and anticholinesterases. 
Anticholinesterases augment the action of suxamethonium[2]. 
Adverse effects 
Because suxamethonium consists of two acetylcholine molecules (diacetylcholine), it is 
understandable that its adverse effects mimic those of acetylcholine. Suxamethonium has effects 
on cholinergic receptors all over the body, including striated muscle and autonomic nervous 
system (Table 1). Suxamethonium has effects on both autonomic ganglia and cardiac muscarinic 
receptors. Depending on the actual status of the patient's autonomic nervous system, it may 
cause bradycardia, tachycardia or other arrhythmias, and hypo- or hypertension. These effects can 
be prevented by administration of anticholinergic drugs, like atropine or glycopyrrolate. 
 
Suxamethonium typically causes fasciculations before the onset of neuromuscular block. Many 
patients have also muscle pains which are more common in young muscular adults. They can be 
rather effectively prevented with a small dose of non-depolarizing neuromuscular drug. 
 
Hyperkalemia and malignant hyperthermia are two life-threatening adverse effects. Plasma 
potassium concentrations often rise, but without clinical consequences in otherwise healthy 
patients. However, in patients with upper or lower motoneuron lesions, trauma, burns or 
immobilization, the number of extrajunctional acetylcholine receptors may be increased so much 
that their activation causes life-threatening hyperkalemia. Suxamethonium can trigger malignant 
hyperthermia, a rare autosomal dominant condition that may be fatal without prompt 
administration of dantrolene and effective symptomatic treatment. 
 
Large doses or prolonged administration of suxamethonium may cause a transition of typical 
depolarizing block to phase II block which resembles the block produced by non-depolarizing 
neuromuscular drugs. Phase II block is not observed following an intubation dose of 
suxamethonium. 
Pharmacokinetics and pharmacodynamics of suxamethonium 
The duration of action of suxamethonium is 4 to 12 minutes following an intubation dose because 
it is rapidly metabolized by plasma pseudocholinesterase. Actually, only a small fraction of the 
administered dose reaches the neuromuscular end plate. The drug is thus not metabolized at the 
neuromuscular junction itself: in order to terminate its effect, it must diffuse back out of the 
neuromuscular junction into systemic circulation, where plasma pseudocholinesterase degrades it 
into choline and succinylmonocholine (with the latter being further metabolized to choline and 
succinic acid)[2]. Several genetically determined forms of plasma pseudocholinesterase exist, and 
this may affect the duration of action of suxamethonium. Approximately 2.5-4% of the population 
is carrying one abnormal gene allele, which prolongs the action of suxamethonium by 50 to 100%. 
Another 0.04% of the population is carrying two abnormal gene alleles, and this prolongs the 
duration of neuromuscular block to 2-6 hours[20]. 
Clinical pharmacology of suxamethonium 
Because of its numerous adverse effects, the clinical use of suxamethonium has been declining. It 
is mainly used to facilitate endotracheal intubation, and for rapid sequence inductions in particular 
because it has the fastest, most reliable onset (with a consistent deep block). However, many 
authorities nowadays consider rocuronium[21] a suitable alternative even for rapid sequence 
induction because it can easily and rapidly be reversed with sugammadex if necessary (see below). 
Suxamethonium also continues to be used for short-lasting muscle relaxation needed during 
electroconvulsive therapy or for the reposition of dislocated joints, and to treat laryngospams. 
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Optimal level of neuromuscular block 
Immobility is an essential part of balanced anaesthesia. Regardless of the surgical procedure, the 
patient should not move after a noxious stimulus. It is impossible to perform surgery if the patient 
is wiggling around and trying to escape the operating table. For some types of surgery, it is 
imperative the patient does not move because it would cause irreparable harm, e.g. during intra-
ocular or intra-cranial surgery. 
 
Muscle relaxation is needed when the force or pressure generated by that force makes it 
impossible to complete the surgical procedure, the typical example being intra-abdominal surgery. 
The high intra-abdominal pressures resulting from the force generated by the diaphragm and 
abdominal wall muscles make it impossible to perform open abdominal surgery and (somewhat 
more controversial, see further) laparoscopic intra-abdominal surgery. Similarly, relocation of a 
hip prosthesis may need relaxation. 
 
Although immobility can be produced very selectively with neuromuscular blocking drugs, the 
question remains, how much neuromuscular block is enough to provide immobility and surgical 
relaxation. What is regarded as adequate surgical relaxation is dependent on a multitude of 
factors. It is not only the degree of neuromuscular block that determines the adequacy of muscle 
relaxation - depth of anaesthesia, type of surgery and surgical skill all have an influence. For 
superficial surgery, immobility is obviously required but the surgery itself does not require any 
significant muscle relaxation. For intra-abdominal surgery, deeper muscle relaxation may be 
required. What degree of neuromuscular block is needed to provide adequate surgical relaxation 
for what procedure has been poorly explored and is only beginning to be studied in randomized 
controlled trials. 
 
For many surgical procedures, balanced anaesthesia does not need to entail the use of 
neuromuscular blocking drugs. Fast track cardiac surgery has been performed without muscle 
relaxants once the airway has been secured[22]. Surgeons rated operating conditions in the 87 
patients as satisfactory, and no reversing agents were needed because the TOF ratio had 
recovered spontaneously to 0.90 by the end of the operation.  
 
In accordance with the previous study, suxamethonium for facilitating endotracheal intubation 
was the only neuromuscular blocking drug which was needed in 86 patients undergoing spinal 
surgery with total intravenous anaesthesia[23]: muscle relaxation was deemed sufficient and the 
surgery was successful, regardless of whether atracurium was used later during surgery or not. An 
isoflurane-fentanyl anaesthetic alone produced also good to excellent surgical field conditions in 
approximately two thirds of patients undergoing radical retropubic prostatectomy without the use 
of neuromuscular blocking drug. Thus, the authors concluded, that the routine use of muscle 
relaxants in adequately anaesthetized patients undergoing this procedure may not be indicated[24]. 
 
During laparoscopic abdominal surgery, a CO2 pneumoperitoneum is usually needed to allow the 
surgeon to visualize the abdominal contents and to provide sufficient working space. Because the 
pressure generated by the abdominal wall muscles and diaphragm is believed to reduce the space 
provided by the pressurized CO2, neuromuscular blocking drugs are administered in the belief that 




One study that did find a difference (i.e. better surgical conditions with a deep[25] versus shallow 
block) was criticized because depth in the control group was not tightly controlled and because 
the average quality of the visual field did not differ[26]. Another study claiming ”marginally better” 
surgical space conditions with deep rather than moderate muscle relaxation during laparoscopic 
cholecystectomy[27] suffered from similar flaws, with the authors basically comparing deep versus 
very shallow or minimal block for a considerable portion of the surgical procedure. When patients 
were randomized to a deep (PTC 2–3) or a moderate neuromuscular block (TOF count 1–2) during 
laparoscopic bariatric surgery[28], a deep neuromuscular block was associated with better surgical 
visualisation and lower pain scores in the immediate postoperative period (p = 0.03) (see Figure 
11.3). 
 
Two recent systematic reviews tried to clarify whether surgical conditions and patient outcome 
are related to the degree of neuromuscular block during surgery. Interestingly, the two reviews 
arrived at different conclusions. While Madsen et al. concluded that deep neuromuscular block 
may improve surgical conditions in laparoscopic and open abdominal surgery[29], Kopman and 
Naguib[30] stated that there are little objective data to demonstrate that a deep neuromuscular 
block (PTC ≥ 1 with TOF twitch count = 0) improves surgical conditions or patient outcome 
compared to a moderate block (TOF twitch count = 1-3). Kopman and Naquib were also concerned 
about the economic consequences of the increasing use of sugammadex which cannot be avoided 
if a deep neuromuscular block is deemed necessary until the very end of surgery. More 
information can be found in 2 editorials that discuss the relationship between surgical muscle 
relaxation and degree of neuromuscular block and that try to define “adequacy of muscle 
relaxation”[31,32]. 
 
To summarize, for many surgical procedures no consensus has been reached regarding the 
optimal level of neuromuscular blocking drug-induced block. While different types of operations 
need different levels of muscle relaxation, it is important to realize this depends on both the depth 
of anaesthesia and the degree of neuromuscular block: deeper levels of anaesthesia may allow 
shallower neuromuscular block to obtain the same degree of relaxation. The price to pay for using 
a deep level of anaesthesia as an essential component of muscle relaxation is prolonged 
emergence. If surgery requires deep muscle relaxation until the very end of surgery and if this 
accomplished by deep level of drug-induced neuromuscular block (e.g. a PTC of 1-3), sugammadex 
can be used to antagonize the block, but this comes with a price tag; the only alternative under 
these conditions is to wait for the spontaneous recovery. 
Factors affecting the requirements of neuromuscular blocking drugs 
The dose of neuromuscular blocking drugs obviously depends on the desired degree of 
neuromuscular block. However, there are other factors that affect the requirements of 
neuromuscular blocking drugs. 
 
Drug-drug interactions 
Drugs that inhibit plasma cholinesterase may delay neuromuscular recovery after suxamethonium 
administration. These drugs include anticholinesterase inhibitors (donepezil, ecothiopate, 
neostigmine, pyridostigmine, rivastigmine etc.), antineoplastic drug cyclophosphamide, 
bambuterol and the monoamine oxidase inhibitor phenelzine[33]. 
 
Enzyme inducing drugs like rifampicin and older antiepileptic drugs antagonize the neuromuscular 
blocking effects of rocuronium, probably by enhancing their hepatic elimination (although other 
mechanisms may also contribute)[34]. The mechanism by which phenytoin and carbamazepine 
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antagonize cisatracurium is not known[35,36]. Enzyme induction or inhibition does not affect 
mivacurium[37]. 
 
Volatile anaesthetics potentiate the effects of non-depolarizing muscle relaxants in a dose-
dependent manner, an effect most pronounced with desflurane (Figure 11.4)[38]. The underlying 
mechanism remains controversial, and several factors have been invoked: increased muscle blood 
flow, increased sensitivity of the motor end-plate, decreased release of acetylcholine, change of 
ion-channel conductance, or other effects at central nervous system. 
 
Aminoglycosides, polymyxins, lincomycin and clindamycin all can potentiate a neuromuscular 
block[33] by inhibiting the prejunctional release of acetylcholine and by depressing postjunctional 
acetylcholine receptor sensitivity to acetylcholine. 
 
Hypothermia 
Hypothermia affects the pharmacokinetics and/or pharmacodynamics of non-depolarizing 
neuromuscular blocking drugs[39]. Hypothermia at 30.4 °C causes a 50 % reduction in rocuronium 
plasma clearance, reducing rocuronium requirements in a hypothermic patient[40]. Hypothermia 
also reduces the Hoffman elimination process which prolongs the action of cisatracurium[41,42]. 
Hypothermia also affects the neuromuscular monitoring process itself: if the monitored arm 
becomes hypothermic, the onset and duration of action of the drugs will become slower and 
longer, respectively, than in the more centrally located muscles (e.g. abdominal wall and 
diaphragm) at normal core temperature[43]. 
 
Dosing of neuromuscular blocking drugs 
Initial administration 
A relative overdose administered as an intravenous bolus achieves the most rapid onset of 
neuromuscular block during induction of anaesthesia. The blood rapidly transports the drug to the 
neuromuscular junctions of the body where its pharmacologic effects take place. The initial dose is 
higher than that required to attain those peak concentration levels needed at the neuromuscular 
junction to facilitate endotracheal intubation. Typically, the initial dose is two to four times the 
ED95. ED95 is the dose which is required to induce a 95% neuromuscular block (the height of the 
first twitch in the train-of-four sequence reaches 5% of the height of the control twitch obtained 
before the administration of neuromuscular blocking drugs). In general, the accompanying 
overshoot is not deleterious because a moderate overdose of modern competitive neuromuscular 
blocking drugs has little or no adverse effects. However, the prolonged duration of drug effect can 
be problematic for short procedures. 
Intermittent bolus dosing 
Most often, a neuromuscular block is maintained by repeated bolus doses. Because of the large 
margin of safety (or neuromuscular reserve) of the neuromuscular junction, the maintenance dose 
is considerably smaller than the induction dose: even though monitoring shows the block induced 
by the loading dose is recovering, up to 70% of the postjunctional nicotinic receptors may still be 
blocked, a condition under which even a small top up dose can have a profound effect on the 
twitch response. Figure 11.5 shows the time course of neuromuscular block following intermittent 
bolus doses. The degree of neuromuscular block varies throughout the procedure, reaching barely 
adequate levels just before administration of the maintenance dose and usually achieving 
complete block for a period thereafter. 
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Continuous infusion 
One way to improve stability of the neuromuscular block over time is to start an infusion once the 
muscle starts to recover from the induction dose (Figure 11.6). The infusion rates of most 
neuromuscular blocking drugs to accomplish this have been published. Typical values for rates of 
infusion required to maintain neuromuscular block constant at 95% are given in Table 1. However, 
because of major interindividual differences, it is important to quantify the degree of 
neuromuscular block repetitively and adjust the rate of infusion accordingly.  
Computer-controlled infusion 
Short-acting neuromuscular blocking drugs can also be administered via a computer-controlled 
infusion. Both target-controlled and closed-loop controlled systems have been described. At least 
theoretically, target-controlled infusion systems are able to attain and maintain the desired 
concentration of the neuromuscular blocking drug. Vermeyen et al. and Motamed et al. have 
described a target-controlled infusion system for the infusion of rocuronium[44,45] and Ma et al.[46] 
for cisatracurium.  
 
Although the target-controlled infusion of neuromuscular blocking drugs can obviously maintain 
the concentrations at a reasonably constant level, they cannot be used without the monitoring of 
neuromuscular block. Without adaptation of the model parameters during drug administration, 
the control of neuromuscular block is far from optimal as compared to closed-loop control of 
neuromuscular block. The values for median performance error and median absolute performance 
error (expressed as median with range) during target-controlled infusion of rocuronium were 9.7 
(-35, 40) and 23.6 (5, 40) % without adaptation of the model parameters and 14.8 (11, 44) and 16 
(13, 44) % with Bayesian forecasting of parameters[45]. These figures are far from the values of 
median performance error and median absolute performance error obtained for closed loop 
control of rocuronium infusion. For instance, Kansanaho and Olkkola[47] observed that the values 
of median performance error and median absolute performance error (expressed as median with 
25th and 75th percentile) were 0.5 (0.0, 0.9) and 1.3 (1.1, 1.7) %, respectively. 
 
Figure 11.7 depicts the typical course of neuromuscular block during closed-loop control. The 
closed-loop system can be started any time after the initial bolus, and will deliver only that 
amount of drug needed to achieve the target neuromuscular block level. Theoretically, it should 
be able to render a neuromuscular block even more stable than with continuous infusions. Long-
acting drugs are less suitable for use with closed-computer-controlled infusion because fewer 
dose adjustments will be needed – and it is precisely that what a computer-controlled infusion is 
well suited for. While it could be applied during long-term sedation in the intensive care unit, any 
benefit should be weighed against that of using short-acting drugs in this context, a benefit not 
likely to be clinically relevant. 
 
A closed-loop system is used to steer drug delivery by the computer-controlled pump (also see 
Weber chapter). Actually, neuromuscular blocking drugs were amongst the first anaesthetic drugs 
to be administered with this technology (see below). The first component is a signal quantifying a 
patient’s neuromuscular block. The signal obtained automatically and repeatedly is fed back to a 
controller where it is compared to a desired “target”. The computer then applies algorithms on 
the various inputs it receives from the actual and desired states of neuromuscular block. Time and 
time-differences can also be used as inputs for the algorithm. Next, the computer adjusts the 




The advantages of closed-loop infusions of neuromuscular blocking drugs are several-fold. First, it 
allows anaesthesiologists to focus on other aspects of care by freeing up time that may otherwise 
be needed for tedious repetitive dose calculations. It may also avoid “cognitive-overload” in 
particularly complex cases. Second, complex control algorithms can be implemented, allowing one 
to achieve a more stable neuromuscular block more rapidly than is possible with direct human 
control. Finally, control algorithms can more accurately monitor dosing histories, provide 
feedback, or trigger alarms to warn the anaesthesiologist about potential over- or under-dosing. 
 
Of course, these systems have disadvantages as well. First, some systems require time and 
attention to be set up. This includes entering patient covariates (weight, age, etc.), neuromuscular 
block targets, filling and placement of syringes. For some systems, these tasks have to be 
completed before anaesthesia can be started. This increases clinical workload during the busy 
induction period, precisely when clinicians need to focus on a host of other factors. Second, 
increased technical complexity may introduce new sources of error and failure. Patient 
information can be entered incorrectly, syringes can be empty and/or need replacement, syringes 
can be incorrectly filled, etc. Understanding potential workflow errors and their consequences for 
patient care (as well as preventing them) is a complex undertaking. 
 
Despite the fact that closed-loop control of neuromuscular blocking drugs has a surprisingly long 
history, and despite a plethora of closed-loop systems described in anaesthesia research, no such 
systems have found broad commercial application. One reason for this are the limitations inherent 
in many of the control algorithms. For example, adaptive and model-based systems “learn” 
individual characteristics based on the history of applied doses and recorded responses, which 
means the computer needs to have all dosing information. This precludes clinicians from dosing 
“along-side” a control system because doses given by the clinician outside of the control algorithm 
may be interpreted by the algorithm as increased sensitivity of the patient to neuromuscular 
blocking drugs. The algorithm may consequently administer lower drug doses than needed to 
maintain the desired effect, because it will rely on this (incorrect) high sensitivity and decrease the 
injection rate. Complex stability issues can occur, causing poor performance resulting in a clinically 
insufficient neuromuscular block.  
 
Avoiding the potential issues with complex control algorithms requires abandoning some degrees 
of “adaptation” in the control algorithm. This has been successful in some ways: a simple non-
adaptive proportional-integrative-derivative controller combined with a lookup-table for TOF 
counts has been shown to achieve good stability in muscle relaxation, while maintaining adequate 
performance despite relaxant dosing “along-side” the control algorithm[48]. The system even 
performed adequately during power-cycling (switching it off and then on again) during the surgical 
procedure. Despite some initial system development, the proposed system was never offered 
commercially. 
 
Reversal of neuromuscular block 
If the effect of neuromuscular blocking drugs is not monitored with objective methods, the patient 
is at risk for residual neuromuscular block at the end of the procedure. If the patient is extubated 
before the TOF ratio has reached at least 0.9, there is an increased risk for reduced acute hypoxic 
ventilatory response and aspiration (the laryngeal muscles that prevent this from happening are 
very sensitive to neuromuscular blocking drugs). Because the risk of postoperative complications is 
markedly increased in patients with a postoperative residual neuromuscular block[49], a residual 
neuromuscular block has to be antagonized. The action of suxamethonium cannot be reversed. If 
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it would cause a prolonged block (e.g. in a patient with atypical pseudocholinesterases), the 
patient has to be ventilated until the block has worn off. Theoretically one could also administer 
fresh frozen plasma, but it usually regarded safer to wait for the recovery of the neuromuscular 
block.  
 
The action of non-depolarizing neuromuscular blocking drugs, however, can be pharmacologically 
reversed. The conventional way of antagonizing the neuromuscular block is the administration of 
anticholinesterases together with anticholinergic drugs. Because non-depolarizing neuromuscular 
drugs produce the block by competitive antagonism, the effect can be overcome and reversed by 
increasing the concentration of the agonist acetylcholine. The most commonly used 
anticholinesterases are neostigmine and edrophonium which are combined with glycopyrrolate or 
atropine to counteract the stimulation of muscarinic receptors. The onset time of neostigmine 
matches that of glycopyrrolate while the onset time of edrophonium matches that of atropine. 
When using anticholinesterases, reversal should not be attempted until the recovery of the 
neuromuscular junction can be observed. Deep neuromuscular block cannot be antagonized with 
anticholinesterases. At least two, but preferably three to four twitches should be observable in the 
train-of-four sequence. Anticholinesterases can be used to antagonize the block induced by any of 
the non-depolarizing neuromuscular drugs. 
 
The action of the aminosteroid rocuronium can also be antagonized with the cyclodextrin 
derivative sugammadex. Sugammadex forms tight complexes with rocuronium. After 
administration of sugammadex the free concentration of rocuronium decreases rapidly. The 
resulting concentration gradient between plasma and neuromuscular junction rapidly decreases 
the concentration of rocuronium at the postjunctional nicotinic receptors, terminating 
rocuronium’s neuromuscular blocking effect within minutes. The sugammadex-rocuronium 
complex is excreted unchanged into urine, and has an elimination half-life of approximately two 
hours. Sugammadex is effective at any depth of neuromuscular block; its efficacy is not affected by 
the type and depth of anaesthesia[50]. 
 
Prior administration of sugammadex affects subsequent rocuronium dosing requirements. 
According to the manufacturer’s recommendation, after 4 mg/kg of sugammadex, no rocuronium 
should not be given in the ensuing 5 minutes. If rocuronium were to be given within this 5-minute 
period, the dose should be 1.2 mg/kg. Even then, the onset of neuromuscular block is delayed and 
the duration action is likely to be markedly reduced. After 16 mg/kg of sugammadex, the 
manufacturer recommends not to use rocuronium for 24 h. If a neuromuscular blocking drug is 
required soon after the administration of sugammadex, most anaesthesiologists would choose 
one of the benzylisoquinolone derivatives, because their action is not modified by sugammadex. 
 
Conclusions and recommendations 
Immobility and sufficient surgical muscle relaxation are essential components of balanced 
anaesthesia. Although they can be accomplished selectively with neuromuscular blocking drugs, 
adequate muscle relaxation during anaesthesia also depends on the depth of anaesthesia. 
 
Although neuromuscular blocking drugs have been administered by continuous infusion and with 
computer controlled infusion, an intermittent bolus is the more frequently used administration 
method. The initial dose of non-depolarizing neuromuscular blocking drugs is normally 2-4 times 
the ED95 dose, followed by smaller doses to maintain the neuromuscular block. 
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The degree of neuromuscular block should always be measured with objective monitoring 
methods. Full neuromuscular recovery (TOF ratio > 0.90) must be ensured before the waking up of 
the patient at the end of the anaesthetic. Residual neuromuscular block considerably increases the 





Legends to the illustrations 
 
Figure 11.1. Monitoring of neuromuscular block with the Mechanosensor is based on bending of 
a piezoelectric sensor. 
 
Figure 11.2. Left panel: Simulated effect site concentrations of rocuronium and cisatracurium after 
the administration of one ED95 dose of each drug. Right panel: Context-sensitive 50% effect 
decrement times as a function of the duration of rocuronium and cisatracurium infusions which 
maintained neuromuscular block (and effect site concentration) constant. Simulation were based 
on the parameters obtained from Ploeger[51], Kleijn[52], Proost[53], Schmith[54], Liu[55], and Tran[56]. 
 
Figure 11.3. Influence of deep relaxation on surgical conditions scored with Leiden-surgical rating 
scale (L-SRS, mean with 95% CI) from 1 (extremely poor) to 5 (optimal conditions) in laparoscopic 
bariatric surgery. *Mann-Whitney-U test P < 0.01 versus moderate block. 
 
Figure 11.4. The rate of infusion cisatracurium maintaining neuromuscular block constant at 90% 
in patients anaesthetized with desflurane, isoflurane, sevoflurane or propofol. *P < 0.02 as 
compared to the other groups, **P < 0.002 as compared to patients with volatile anaesthetics. 
 
Figure 11.5. Maintenance of neuromuscular block using intermittent bolus dosing. The degree of 
neuromuscular block varies throughout the procedure between barely adequate and complete 
neuromuscular block. 
 
Figure 11.6. Maintenance of neuromuscular block using a continuous infusion. Compared to the 
intermittent bolus dosing, the degree of neuromuscular block varies considerably less throughout 
the procedure. 
 




Table 1. Effect of commonly used neuromuscular blocking drugs on the autonomic nervous system and histamine release and their basic 
pharmacokinetic and pharmacodynamic properties 
 
 
ED95 is the dose which is required to induce a 95% neuromuscular block (the height of the first twitch in the train-of-four sequence reaches 5% of the 
height of the control twitch obtained before the administration of neuromuscular blocking drugs) 
  
Drug Chemical structure 
Autonomic nervous system and 
histamine release 




















2 × ED95 
(min) 
Time to T1 









Cisatracurium Benzylisoquinoline None None None 0.05 1-2 5.2 20-50 16 
Mivacurium Benzylisoquinoline None None Slight 0.08 3-15 3 10-20 < 5 





1.5 20-50 10-25 
Suxamethonium Diacetylcholine Stimulates Stimulates Slight 0.3 - 1.4 < 10 < 2 
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Table 2. Population pharmacokinetic and pharmacodynamic variables for non-depolarizing neuromuscular blocking drugs. 
 
 Author Subgroup Pharmacokinetics Pharmacodynamics 

























kip=0.374 1/min (plasma-interstitial) 
kei=0.151 1/min (interstitial-effect) 
Ce50=98 mg/ml 
λ=3.7 























Q2rac·0.279· (WGT/70)0.75  
Q2rac=1-(Asian)0.212 














WGT=bodyweight in kg; AGE=age is years; CR=creatinine clearance in ml/min; Asian=1 for asian, 0 otherwise; Sev=1 for Sevoflurane anesthesia, 0 otherwise. 
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